BIOTRICITY INC.: 10-Q filed 2016-05-19
What BIOTRICITY INC. reported in its quarterly report filed 2016-05-19 (fiscal Q1 2016): 16 published measures, 33 facts as tagged in accession 0001511164-16-000858.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2016-05-19
- Fiscal period
- fiscal Q1 2016
- Accession
- 0001511164-16-000858 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIOTRICITY INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 159,485 | USD | |
| At 2015-12-31 | 519,094 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 2,729,463 | USD | |
| At 2015-12-31 | 1,758,271 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | -2,569,978 | USD | |
| At 2015-12-31 | -1,239,177 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 53,643 | USD | |
| At 2015-12-31 | 410,601 | USD | |
| At 2015-03-31 | 135,295 | USD | |
| At 2014-12-31 | 448,599 | USD |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | -545,791 | USD | 91 |
| 2015-01-01 to 2015-03-31 | -586,133 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 225,724 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 235,379 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | -10,497,925 | USD | |
| At 2015-12-31 | -9,228,774 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 1,273,670 | USD | 90 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 694,789 | USD | |
| At 2015-12-31 | 413,273 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 576,620 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 1,806,405 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 241,534 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 367,194 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 15,876,947 | shares | |
| At 2015-12-31 | 9,123,031 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 7,982,466 | USD | |
| At 2015-12-31 | 7,982,598 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 15,593 | USD | |
| At 2015-12-31 | 139,218 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | -1,269,151 | USD | 91 |
| 2015-01-01 to 2015-03-31 | -1,806,405 | USD | 90 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 335,086 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 1,439,211 | USD | 90 |
Inspect the source
- Entity
- BIOTRICITY INC. / CIK 0001630113
- Captured
- 2026-09-21T17:22:14.606Z
- SEC response SHA-256
de56e3354d4180362d8bf36a6dd02ff7fd0db9690bc31c81e452959deb9a8d37
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001630113.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))